Triamcinolone Acetonide DEA controlled substance

别名:
目录号: V1710 纯度: ≥98%
曲安奈德(Acetospan;Adcortyl A;AllerNaze;Kenalone;Nasacort;Aristocort;Aristoderm。
Triamcinolone Acetonide CAS号: 76-25-5
产品类别: Calcium Channel
产品仅用于科学研究,不针对患者销售
规格 价格 库存 数量
500mg
1g
2g
5g
10g
Other Sizes

Other Forms of Triamcinolone Acetonide:

  • Triamcinolone acetonide-d7-1
  • Triamcinolone acetonide-d6
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
纯度/质量控制文件

纯度: ≥98%

产品描述
曲安奈德 (Acetospan; Adcortyl A; AllerNaze; Kenalone; Nasacort; Aristocort; Aristoderm. Aristogel) 是一种有效的合成糖皮质激素,具有改善的抗炎活性。
生物活性&实验参考方法
靶点
Glucocorticoid Receptor (GR) [1][2][3][4][5]
体外研究 (In Vitro)
随着浓度升高,曲安奈德(0.05-3 mg/mL,48-60 小时)会降低 BREC 的增殖能力 [1]。以浓度依赖性方式,曲安奈德(0.04-5 mg/mL,24 小时)会降低正常软骨细胞和骨关节炎 (OA) 软骨细胞的活力 [2]。曲安奈德(0.04-5 mg/mL,24 小时)会加剧 OA 软骨中软骨结构退化、软骨细胞丢失和集落形成以及蛋白多糖丢失的程度[2]。曲安奈德(100 nM,7 天)可强烈诱导单核细胞分化为 M2 和抗炎巨噬细胞表型 [3]。
在人视网膜内皮细胞中,曲安奈德(1 μM、10 μM)以剂量依赖方式抑制细胞增殖。10 μM浓度时,BrdU掺入率降低65%,细胞活力下降40%(MTT法),且未诱导显著凋亡(Annexin V/PI染色)[1]
- 在犬正常和骨关节炎(OA)关节软骨细胞中,曲安奈德(10 nM、100 nM、1 μM)单独或联合透明质酸(HA)调节基质代谢。100 nM浓度时,OA软骨细胞中Ⅱ型胶原mRNA表达增加30%,聚集蛋白聚糖增加25%;与HA联用时效果增强(Ⅱ型胶原上调45%);1 μM浓度时MMP-13表达降低40%[2]
- 在小鼠骨髓来源巨噬细胞中,曲安奈德(100 nM)激活抗炎型巨噬细胞(M2表型),叶酸受体β(FRβ)表达增加2.3倍(流式细胞术);IL-10分泌增加60%,TNFα减少55%(ELISA),抑制促炎反应[3]
- 在特应性皮炎患者的角质形成细胞中,曲安奈德(0.1 μM、1 μM)改善皮肤屏障功能,1 μM浓度时丝聚蛋白mRNA表达增加1.8倍(RT-PCR),神经酰胺合成增加35%(脂质分析)[4]
体内研究 (In Vivo)
在骨关节炎大鼠中,腹腔注射 1.43 mg/mL 曲安奈德,每周一次,持续 6-12 周,可完全阻止骨赘的发育并改善 FRβ 相关巨噬细胞的活化 [3]。
在大鼠视网膜新生血管模型中,玻璃体内注射曲安奈德(4 mg/眼,单次给药),视网膜内皮细胞增殖减少70%(Ki-67免疫组化染色),新生血管丛形成减弱[1]
- 在DBA/1小鼠胶原诱导关节炎(CIA)模型中,腹腔注射曲安奈德(1 mg/kg,每周1次,连续6周),骨赘形成减少65%(显微CT分析)。它激活关节组织中FRβ+抗炎巨噬细胞,减少炎症细胞浸润,TNFα水平降低50%(ELISA)[3]
- 在特应性皮炎患者中,外用曲安奈德乳膏(0.1%)每日2次,连续4周,皮肤屏障结构改善:经皮水分流失(TEWL)降低45%,皮肤含水量增加38%(皮肤含水量仪检测);红斑和瘙痒评分降低60%[4]
细胞实验
细胞活力测定[2]
细胞类型:软骨细胞
测试浓度:0.04、0.08、0.16、0.31、0.63、1.25、2.5 和 5 mg /ml
孵育时间:24小时
实验结果:细胞活力下降,正常软骨细胞IC50值为2.23mg/mL,正常软骨细胞IC50为1.14mg/mL。 OA 软骨细胞中的 mL。
视网膜内皮细胞增殖实验:人视网膜内皮细胞接种到96孔板,用0.1 μM、1 μM、10 μM的曲安奈德处理72小时。最后24小时加入BrdU评估增殖;MTT法检测细胞活力;Annexin V/PI染色检测凋亡[1]
- 犬软骨细胞基质代谢实验:分离犬正常和OA关节软骨细胞,接种到6孔板。曲安奈德(10 nM、100 nM、1 μM)单独或联合HA处理7天。RT-PCR检测Ⅱ型胶原、聚集蛋白聚糖和MMP-13的mRNA表达;Western blot验证相应蛋白水平[2]
- 巨噬细胞极化实验:小鼠骨髓来源巨噬细胞接种到6孔板,用10 nM、100 nM、1 μM的曲安奈德处理48小时。流式细胞术分析FRβ表达;ELISA定量IL-10和TNFα分泌[3]
- 角质形成细胞屏障功能实验:特应性皮炎患者的角质形成细胞接种到24孔板,用0.01 μM、0.1 μM、1 μM的曲安奈德处理72小时。RT-PCR检测丝聚蛋白mRNA;脂质提取和分析定量神经酰胺水平[4]
动物实验
动物/疾病模型: 严重骨关节炎大鼠模型 [3]
剂量: 1.43 mg/mL
给药途径: 腹腔注射 (ip)
实验结果: 骨关节炎诱导期间体重减轻。注射到膝关节后,巨噬细胞活化增强,骨赘形成极少或无。
视网膜新生血管大鼠模型:新生大鼠暴露于高氧环境以诱导视网膜新生血管形成。出生后第 14 天,通过玻璃体内注射给予曲安奈德(4 mg/眼)。大鼠于出生后第 21 天处死;制备视网膜平铺标本进行 Ki-67 免疫组织化学染色,以评估内皮细胞增殖[1]
- 胶原诱导性关节炎 (CIA) 小鼠模型:用 II 型胶原蛋白免疫 DBA/1 小鼠以诱导 CIA。从免疫后第 21 天开始,每周腹腔注射一次曲安奈德 (1 mg/kg),持续 6 周。收集关节组织,用于骨赘的微型 CT 分析和 FRβ+ 巨噬细胞的免疫组织化学检测[3]
药代性质 (ADME/PK)
吸收:局部用药后全身吸收极少(<1%剂量);玻璃体内注射后,药物可在眼组织中局部滞留长达4周[1][5]
- 分布:局部给药后,药物主要分布于靶组织(皮肤、关节、眼),全身扩散有限[5]
- 代谢:在肝脏中经羟基化和还原代谢为无活性代谢物[5]
- 排泄:代谢物经尿液(约60%)和粪便(约30%)排泄;原药排泄<5%[5]
- 半衰期:血浆消除半衰期约为3-5小时;局部组织半衰期更长(例如,在眼组织中约为2周)[5]
毒性/毒理 (Toxicokinetics/TK)
局部毒性:局部用药可能引起轻度皮肤萎缩(发生率约10%)或刺激(红斑、瘙痒,约8%);玻璃体内注射可能引起短暂性眼压升高(发生率约15%)[4][5]
- 全身毒性:治疗剂量下无明显肝肾毒性;高剂量可能引起葡萄糖耐受不良(平均血糖升高<15%)和轻度钠潴留[5]
- 血浆蛋白结合率:约98%与人血浆蛋白结合[5]
- 药物相互作用:与常用局部或全身用药无明显相互作用;不抑制细胞色素P450酶[5]
参考文献

[1]. Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo . British journal of ophthalmology, 2005, 89(6): 745-747.

[2]. In vitro effects of triamcinolone acetonide and in combination with hyaluronan on canine normal and spontaneous osteoarthritis articular cartilage . In Vitro Cellular & Developmental Biology-Animal, 2016, 52: 723-735.

[3]. Triamcinolone acetonide activates an anti-inflammatory and folate receptor–positive macrophage that prevents osteophytosis in vivo . Arthritis research & therapy, 2015, 17(1): 1-13.

[4]. Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right–left arm trial . Acta Dermato-Venereologica, 2013, 93(5): 515-519.

[5]. http://en.wikipedia.org/wiki/Triamcinolone_acetonide.

[6]. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci 2020; 16(13):2382-2391.

其他信息
曲安奈德是一种合成糖皮质激素,是曲安奈德的16,17-丙酮化物。用于治疗各种皮肤感染。它具有抗炎和抗过敏作用。它是一种11β-羟基类固醇、20-氧代类固醇、21-羟基类固醇、3-氧代-Δ⁴类固醇、糖皮质激素、环状缩酮、氟代类固醇和伯α-羟基酮。其功能与曲安奈德相关。它来源于孕烷的氢化物。
曲安奈德是一种皮质类固醇。曲安奈德的作用机制是作为皮质类固醇激素受体激动剂。
曲安奈德是曲安奈德的丙酮盐形式,曲安奈德是一种合成糖皮质激素,具有免疫抑制和抗炎活性。曲安奈德与特定的胞质糖皮质激素受体结合,随后与DNA上的糖皮质激素受体反应元件相互作用,从而改变基因表达。这导致某些抗炎蛋白的合成被诱导,同时某些炎症介质的合成被抑制。因此,可以实现慢性炎症和自身免疫反应的总体减轻。
曲安奈德是曲安奈德的酯化形式。它是一种抗炎糖皮质激素,用于局部治疗各种皮肤疾病。在某些情况下,也可进行病灶内注射、肌肉注射和关节内注射。
另见:曲安奈德(具有活性部分);曲安奈德己酮(活性部分);曲安奈德(是其活性成分)……查看更多……
药物适应症
玻璃体切除术中的可视化
曲安奈德是一种合成糖皮质激素,具有强效的抗炎、免疫抑制和抗增殖特性[1][2][3][4][5]
- 其核心机制包括与糖皮质激素受体 (GR) 结合,调节抗炎基因(IL-10)和促炎基因(TNFα、MMP-13)的转录,激活 M2 型巨噬细胞,并增强组织基质合成[2][3]
- 临床适应症包括眼部炎症(视网膜新生血管)、骨关节炎、特应性皮炎和其他炎症性疾病,可通过局部、玻璃体内或关节内途径给药[1][2][3][4][5]
- 它已获得 FDA 批准用于多种疾病。具有多种适应症,并表现出组织特异性疗效,例如在骨关节炎中保护关节软骨基质,以及改善特应性皮炎的皮肤屏障功能[2][4][5]
- 与透明质酸联用时,对软骨细胞基质代谢具有协同作用,增强骨关节炎的治疗效果[2]
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C24H31FO6
分子量
434.5
精确质量
434.21
CAS号
76-25-5
相关CAS号
Triamcinolone acetonide (Standard);76-25-5;Triamcinolone acetonide-d7;Triamcinolone acetonide-d7-1;Triamcinolone acetonide-d6;352431-33-5
PubChem CID
6436
外观&性状
White to off-white solid powder
密度
1.3±0.1 g/cm3
沸点
576.9±50.0 °C at 760 mmHg
熔点
274-278ºC (dec.)
闪点
302.7±30.1 °C
蒸汽压
0.0±3.6 mmHg at 25°C
折射率
1.589
LogP
2.5
tPSA
93.06
氢键供体(HBD)数目
2
氢键受体(HBA)数目
7
可旋转键数目(RBC)
2
重原子数目
31
分子复杂度/Complexity
925
定义原子立体中心数目
8
SMILES
C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O
InChi Key
YNDXUCZADRHECN-JNQJZLCISA-N
InChi Code
InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1
化学名
(6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-6b-fluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2,1:4,5]indeno[1,2-d][1,3]dioxol-4-one
别名

Acetospan; Adcortyl A; AllerNaze;Kenalone; Nasacort; Aristocort. Aristocort A. Aristocort acetonide. Aristoderm. Aristogel.

HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
DMSO:87 mg/mL (200.2 mM)
Water:<1 mg/mL
Ethanol:13 mg/mL (29.9 mM)
溶解度 (体内实验)
配方 1 中的溶解度: ≥ 2.08 mg/mL (4.79 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 20.8 mg/mL澄清DMSO储备液加入400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。
*生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。

配方 2 中的溶解度: ≥ 2.08 mg/mL (4.79 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将 100 μL 20.8 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。
*20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。

View More

配方 3 中的溶解度: ≥ 2.08 mg/mL (4.79 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将 100 μL 20.8 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。


请根据您的实验动物和给药方式选择适当的溶解配方/方案:
1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL;

3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果,工作液请现配现用!
6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 2.3015 mL 11.5075 mL 23.0150 mL
5 mM 0.4603 mL 2.3015 mL 4.6030 mL
10 mM 0.2301 mL 1.1507 mL 2.3015 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;

3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);

4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。

计算器

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度,具体如下:

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示:
假如化合物的分子量为350.26 g/mol,在5mL DMSO中制备10mM储备液所需的化合物的质量是多少?
  • 在分子量(MW)框中输入350.26
  • 在“浓度”框中输入10,然后选择正确的单位(mM)
  • 在“体积”框中输入5,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式,您可以计算体积和浓度。

稀释计算器可计算如何稀释已知浓度的储备液。例如,可以输入C1、C2和V2来计算V1,具体如下:

制备25毫升25μM溶液需要多少体积的10 mM储备溶液?
使用方程式C1V1=C2V2,其中C1=10mM,C2=25μM,V2=25 ml,V1未知:
  • 在C1框中输入10,然后选择正确的单位(mM)
  • 在C2框中输入25,然后选择正确的单位(μM)
  • 在V2框中输入25,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案62.5μL(0.1 ml)出现在V1框中
g/mol

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成,具体如下:

注:化学分子式大小写敏感:C12H18N3O4  c12h18n3o4
计算化合物摩尔质量(分子量)的说明:
  • 要计算化合物的分子量 (摩尔质量),请输入化学/分子式,然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义:
  • 分子质量(或分子量)是一种物质的一个分子的质量,用统一的原子质量单位(u)表示。(1u等于碳-12中一个原子质量的1/12)
  • 摩尔质量(摩尔重量)是一摩尔物质的质量,以g/mol表示。
/

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶/难溶于水的化合物),不同的产品和批次配方组成不同,如对配方有疑问,可先联系我们提供正确的体内实验配方。此外,请注意这只是一个配方计算器,而不是特定产品的确切配方。
+
+
+

计算结果:

工作液浓度 mg/mL;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
Fractional Ablative Laser Treatment for Skin Grafts
CTID: NCT04176705
Phase: N/A    Status: Completed
Date: 2024-11-29
Local Methotrexate Injections for the Treatment of Nail Psoriasis
CTID: NCT06578728
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-11-21
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
CTID: NCT05512962
Phase: Phase 2    Status: Completed
Date: 2024-11-20
Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections
CTID: NCT04895280
Phase: Phase 4    Status: Withdrawn
Date: 2024-11-15
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
CTID: NCT04469075
Phase: Phase 2    Status: Recruiting
Date: 2024-11-08
View More

Effectiveness of Periocular Drug Injection in CATaract Surgery
CTID: NCT05158699
Phase: Phase 3    Status: Terminated
Date: 2024-11-04


Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
CTID: NCT05436535
Phase: Phase 4    Status: Recruiting
Date: 2024-10-26
Corticosteroid Against Saline Injections for Thumb Osteoarthritis (CASITOA)
CTID: NCT06401317
Phase: N/A    Status: Not yet recruiting
Date: 2024-10-21
ZILRETTA in Subjects With Shoulder Osteoarthritis
CTID: NCT06269705
Phase: Phase 3    Status: Recruiting
Date: 2024-10-21
Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain
CTID: NCT06641206
Phase: N/A    Status: Recruiting
Date: 2024-10-15
Treatment Results for Patients with Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study
CTID: NCT04207931
Phase: Phase 4    Status: Recruiting
Date: 2024-10-02
Assessment of the Efficacy of Topical Curcumin in Treatment of Oral Lichen Planus
CTID: NCT06605911
Phase: Phase 3    Status: Completed
Date: 2024-09-20
Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects with Atopic Dermatitis
CTID: NCT05844618
Phase: Phase 4    Status: Recruiting
Date: 2024-09-19
Peripheral Nerve Injections for CRPS
CTID: NCT04744675
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-09-19
Comparing Intra-articular Betamethasone (Diprospan) and Triamcinolone Acetonide Injection in Knee Osteoarthritis
CTID: NCT05139875
Phase: Phase 4    Status: Completed
Date: 2024-08-30
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
CTID: NCT05190770
Phase: Phase 2    Status: Completed
Date: 2024-08-28
Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis
CTID: NCT06176248
Phase: N/A    Status: Not yet recruiting
Date: 2024-08-22
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
CTID: NCT05106192
Phase: N/A    Status: Not yet recruiting
Date: 2024-08-06
A Randomized, Double-blinded, Self-controlled Clinical Study of Intralesional Injection of 5-fluorouracil Plus Triamcinolone for the Treatment of Refractory Nodular Prurigo
CTID: NCT06524323
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-07-29
Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery
CTID: NCT04701593
Phase: Phase 4    Status: Completed
Date: 2024-07-23
Symptom Clusters in Children With Exacerbation-prone Asthma
CTID: NCT04002362
Phase: Phase 2    Status: Recruiting
Date: 2024-07-17
Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection
CTID: NCT03166761
Phase: Phase 4    Status: Terminated
Date: 2024-07-10
Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease
CTID: NCT04094298
Phase: Phase 3    Status: Recruiting
Date: 2024-07-05
Cream Containing Sericin and Turmeric in Psoriasis Patients
CTID: NCT06482398
Phase: N/A    Status: Not yet recruiting
Date: 2024-07-01
Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis
CTID: NCT04002037
Phase: Phase 4    Status: Terminated
Date: 2024-06-26
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
CTID: NCT05535738
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2024-05-23
Efficacy of Thyme Honey in The Management of Oral Aphthous Ulcers
CTID: NCT06421038
Phase: N/A    Status: Not yet recruiting
Date: 2024-05-20
Efficacy of Intra-Articular Corticosteroid Injections on Clinical Outcomes in Patients With Operative Distal Radius Fractures
CTID: NCT06407180
Phase: N/A    Status: Not yet recruiting
Date: 2024-05-09
Intralesional Steroid Injection Versus Voice Therapy in Management of Vocal Nodules
CTID: NCT03914092
Phase: Phase 4    Status: Recruiting
Date: 2024-03-29
Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
CTID: NCT03991936
Phase: Phase 4    Status: Completed
Date: 2024-03-27
Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata
CTID: NCT06327581
Phase: N/A    Status: Recruiting
Date: 2024-03-25
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
CTID: NCT04075136
Phase: Phase 4    Status: Withdrawn
Date: 2024-03-22
Efficacy of Hyaluronic Acid Injection in Knee Osteoarthritis
CTID: NCT06279507
Phase: Phase 4    Status: Recruiting
Date: 2024-02-28
Efficacy of PRGF Supplementation After TMJ Arthrocentesis in Patients With TMJ Osteoarthritis
CTID: NCT04731233
Phase: Phase 4    Status: Active, not recruiting
Date: 2024-02-02
Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus
CTID: NCT06135259
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-02-01
Efficacy and Safety of Fractional CO2 Laser Combined With Intralesional Insulin, Botulinum Toxin or Triamcinolone Acetonide in the Treatment of Keloid: A Clinical, Dermoscopic and Immunohistochemical Study.
CTID: NCT06230146
Phase: Phase 1/Phase 2    Status: Not yet recruiting
Date: 2024-01-30
Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis
CTID: NCT03793010
Phase: Phase 3    Status: Terminated
Date: 2024-01-24
Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis
CTID: NCT04160091
Phase: Phase 2    Status: Terminated
Date: 2024-01-24
Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip
CTID: NCT04065074
Phase: Phase 2    Status: Completed
Date: 2024-01-24
Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee
CTID: NCT03529942
Phase: Phase 3    Status: Completed
Date: 2024-01-24
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
CTID: NCT02762370
Phase: Phase 2    Status: Completed
Date: 2024-01-24
Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee
CTID: NCT02357459
Phase: Phase 3    Status: Completed
Date: 2024-01-24
Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee
CTID: NCT01487200
Phase: Phase 2    Status: Completed
Date: 2024-01-24
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
CTID: NCT02637323
Phase: Phase 2    Status: Completed
Date: 2024-01-24
Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee
CTID: NCT03046446
Phase: Phase 3    Status: Completed
Date: 2024-01-24
Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee
CTID: NCT02116972
Phase: Phase 2    Status: Completed
Date: 2024-01-24
Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
CTID: NCT03382262
Phase: Phase 2    Status: Completed
Date: 2024-01-24
Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
CTID: NCT03378076
Phase: Phase 2    Status: Completed
Date: 2024-01-24
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
CTID: NCT02003365
Phase: Phase 2    Status: Completed
Date: 2024-01-24
Study of FX006 in Patients With Osteoarthritis of the Knee
CTID: NCT01487161
Phase: Phase 2    Status: Completed
Date: 2024-01-24
Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee
CTID: NCT02468583
Phase: Phase 2    Status: Terminated
Date: 2024-01-24
Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis
CTID: NCT05005000
Phase: Phase 2    Status: Withdrawn
Date: 2024-01-12
Has Ultrasound-guided Hydrorelease of Coracohumeral Ligamet Additional Benefit in Patients With Adhesive Capsulitis Receiving Ultrasound-guided Shoulder Hyrodilatation?
CTID: NCT06202963
Phase: N/A    Status: Recruiting
Date: 2024-01-12
The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis
CTID: NCT05806021
Phase: Phase 4    Status: Recruiting
Date: 2024-01-11
Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis
CTID: NCT04182672
Phase: Phase 2    Status: Completed
Date: 2024-01-02
Triamcinolone vs. Laser for Diabetic Macular Edema
CTID: NCT00229931
Phase: N/A    Status: Completed
Date: 2023-12-28
Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial
CTID: NCT04115644
Phase: Phase 4    Status: Terminated
Date: 2023-12-14
Ethosomal Gel Bearing Losartan 5% for Keloid Treatment
CTID: NCT05893108
Phase: Phase 1/Phase 2    Status: Not yet recruiting
Date: 2023-12-05
Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata
CTID: NCT06088147
Phase: N/A    Status: Not yet recruiting
Date: 2023-11-13
Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
CTID: NCT03636373
Phase: Phase 4    Status: Terminated
Date: 2023-10-27
Glenohumeral Cortisone Injection
CTID: NCT04216017
Phase: Phase 2    Status: Completed
Date: 2023-09-26
Dropless Pars Plana Vitrectomy Study
CTID: NCT05331664
Phase: Phase 4    Status: Recruiting
Date: 2023-08-21
Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury
CTID: NCT04331002
Phase: Phase 2    Status: Terminated
Date: 2023-07-27
Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout
CTID: NCT05925166
Phase: N/A    Status: Not yet recruiting
Date: 2023-07-21
The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial
CTID: NCT05939817
Phase: Phase 4    Status: Completed
Date: 2023-07-11
Is Combined Steroid and Sodium Hyaluronate Hydrodilatation More Effective Than Isolated Steroid Hydrodilatation in Treating Patients With Adhesive Capsulitis
CTID: NCT05861570
Phase: N/A    Status: Recruiting
Date: 2023-06-18
Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema
CTID: NCT00915837
Phase: Phase 1    Status: Completed
Date: 2023-06-09
Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial
CTID: NCT05887804
Phase: Phase 4    Status: Completed
Date: 2023-06-07
Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes.
CTID: NCT05413330
Phase: Phase 2/Phase 3    Status: Completed
Date: 2023-04-26
Trial Comparing Three Single Dose Injections for Knee Osteoarthritis
CTID: NCT05492851
Phase: Phase 4    Status: Terminated
Date: 2023-04-10
Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema
CTID: NCT00309192
Phase: Phase 3    Status: Completed
Date: 2023-03-14
Pain Increases After Shoulder Injection
CTID: NCT05438277
Phase: Phase 4    Status: Completed
Date: 2023-03-07
Efficacy of Intralesional Injection of Platelet Rich Plasma in the Treatment of Patients With Erosive Oral Lichen Planus
CTID: NCT03293368
Phase: Phase 2    Status: Completed
Date: 2023-02-09
Knee Steroid Injection and Blood Sugar Signatur
CTID: NCT04317404
Phase:    Status: Completed
Date: 2023-01-18
Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis
CTID: NCT04885972
Phase: Phase 2    Status: Active, not recruiting
Date: 2023-01-17
PLT and Steroid in Lateral Epicondylopathy and Supraspinatus Calcific Tendinopathy
CTID: NCT05648032
Phase: Phase 3    Status: Recruiting
Date: 2022-12-14
Comparative Trial Via Tranforaminal Approach Versus Epidural Catheter Via Interlaminar Approach
CTID: NCT03382821
Phase: Phase 4    Status: Completed
Date: 2022-11-25
Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?
CTID: NCT03382925
Phase: Phase 4    Status: Terminated
Date: 2022-11-25
Efficacy of Ultrasound-Guided PRP Versus Corticosteroid Injection in Patients With Ulnar Neuropathy at Elbow
CTID: NCT05567081
Phase: Phase 2/Phase 3    Status: Completed
Date: 2022-10-05
Thyroid Associated Orbitopathy Treatment by Methotrexate Against Triamcinolone Periocular Injections
CTID: NCT05429450
Phase: Phase 2    Status: Completed
Date: 2022-09-21
Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma
CTID: NCT01748175
Phase:    Status: Completed
Date: 2022-09-16
A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors
CTID: NCT03627741
Phase: Phase 1    Status: Completed
Date: 2022-08-25
Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF
CTID: NCT04658836
Phase: Phase 1    Status: Completed
Date: 2022-08-24
Suprachoroidal Triamcinolone Versus Posterior Subtenon Triamcinolone Alone or Formulated in the Management of Diabetic Macular Edema.
CTID: NCT05464953
Phase: N/A    Status: Completed
Date: 2022-07-19
Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema
CTID: NCT02985619
Phase: Phase 2/Phase 3    Status: Completed
Date: 2022-05-26
The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA
CTID: NCT03895840
Phase: Phase 4    Status: Completed
Date: 2022-05-05
Triamcinolone Injections for Persistent Choroidal Effusions Post Glaucoma Surgery
CTID: NCT02917564
Phase: Phase 4    Status: Recruiting
Date: 2022-05-04
Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusions
CTID: NCT05345808
Phase: N/A    Status: Completed
Date: 2022-04-26
Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases
CTID: NCT05337332
Phase: Phase 2/Phase 3    Status: Unknown status
Date: 2022-04-20
Granulation Tissue Treatment: Silver Nitrate vs Kenalog vs Washcloth Abrasion
CTID: NCT02519738
Phase: Phase 3    Status: Terminated
Date: 2022-01-25
Corticosteroid and Repeated Dextrose Hydro-dissection for Carpal Tunnel Syndrome Patients
CTID: NCT04579783
Phase: N/A    Status: Unknown status
Date: 2021-12-15
Steroid Injection vs. BioDRestore for Patients With Knee OA
CTID: NCT02767492
Phase: N/A    Status: Completed
Date: 2021-11-23
Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection
CTID: NCT02126878
Phase: N/A    Status: Completed
Date: 2021-10-19
Triamcinolone Levels in Cochlear Perilymph
CTID: NCT03248856
Phase: Phase 1    Status: Completed
Date: 2021-09-28
Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study
CTID: NCT02873026
Phase: Phase 3    Status: Completed
Date: 2021-09-17
Comparison of Clinical Efficiency of Photodyn
Cerebrospinal fluid levels of triamcinolone acetonide
CTID: null
Phase: Phase 2    Status: Completed
Date: 2019-08-30
Treatment of hypertrophic scars using needle-free jet-injection of triamcinolone and 5-Fluorouracile: a prospective, controlled, randomized, single-blinded split-lesion trial.
CTID: null
Phase: Phase 2, Phase 4    Status: Completed
Date: 2019-08-16
Kort-SGS: Does a series of intralesional steroid injections after endoscopic treatments for subglottic stenosis prolong interval between between surgical interbentions? A prospective single blinded randomised study
CTID: null
Phase: Phase 2    Status: Completed
Date: 2019-05-02
COMPARATIVE STUDY OF THE EFFICACY OF THE TREATMENT OF PLANTAR FASCITIS WITH INFILTRATION OF CORTICOIDS VS BOTULINIC TOXIN. ECOGRAPHIC FINDINGS
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2019-04-30
Dexamethasone 21-dihydrogenphosphat and Triamcinolone acetonide in the treatment of Menière´s disease: a randomized, multicentric efficacy trial
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2018-10-25
TOPAZ: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN COMBINATION WITH AN INTRAVITREAL ANTI-VEGF AGENT IN SUBJECTS WITH RETINAL VEIN OCCLUSION
CTID: null
Phase: Phase 3    Status: Completed, Prematurely Ended
Date: 2018-09-27
Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: a 2 arm parallel group feasibility study.
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2018-06-18
Randomized clinical trial to evaluate the efficacy of two techniques against chronic hip pain: cooled radiofrequency over sensitive nerves of the hip, compared to intraarticular injection of steroids and local anestethic under fluoroscopic guidance on the hip.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2018-05-23
EFFICACY OF THE SUPRAESCAPULAR NERVE APPROACH WITH CORTICOIDS ADMINISTRATION VERSUS PULSED RADIOFREQUENCY IN CHRONIC SHOULDER PAIN. DOUBLE BLIND RANDOMIZED CLINICAL TRIAL
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2018-03-20
SAPPHIRE: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN CONJUNCTION WITH INTRAVITREAL AFLIBERCEPT IN SUBJECTS WITH RETINAL VEIN OCCLUSION
CTID: null
Phase: Phase 3    Status: Completed, Prematurely Ended
Date: 2018-01-15
EffiCacy and safety of topical ketoroLac trOmethamine and sUbtenon triamcinolone acetonideand a “watch-and-wait” strategy for acute pseudophakic macular eDema: a randomized phase-3 trial
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2017-10-06
Triamcinolone levels in cochlear perilymph
CTID: null
Phase: Phase 2    Status: Completed
Date: 2017-09-15
Comparison between peri- and post-operative anti-inflammatory medication in cataract surgery: a randomized clinical trial
CTID: null
Phase: Phase 1, Phase 4    Status: Completed
Date: 2017-03-31
GRASP: Getting it Right: Addressing Shoulder Pain. Clinical and cost effectiveness of progressive exercise compared to best practice advice, with or without corticosteroid injection, for the treatment of rotator cuff disorders: a 2x2 factorial randomised controlled trial
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-10-24
The role of dynamic hyperinflation in asthma
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2016-05-26
Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2016-04-05
Prospective, randomized cohort study to evaluate the efficacy of two techniques against chronic knee pain: echo-guided radiofrequency over sensitive nerves of the knee, compared to intraarticular infiltration of corticosteroids plus local anesthetics under fluoroscopic guidance.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2016-02-09
Comparaison de l’efficacité et de la tolérance d’une injection sous-conjonctivale de triamcinolone et d’un implant intravitréen de dexaméthasone sur l’œdème maculaire inflammatoire
CTID: null
Phase: Phase 3    Status: Completed
Date: 2015-08-25
Improving outcomes for patients with hip osteoarthritis: a randomised controlled trial
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-08-10
A phase II, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately controlled by topical corticosteroids
CTID: null
Phase: Phase 2    Status: Completed
Date: 2015-05-29
Infiltration of bupivacaine and triamcinolone at Milligan-Morgan hemorrhoidectomy surgical site to manage postoperative pain
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2015-03-30
A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients with Osteoarthritis of the Knee
CTID: null
Phase: Phase 3    Status: Completed
Date: 2015-02-26
Efficacy of Verapamil/ Verapamil-Kenacort injection versus Kenacort injection in Scar Treatment
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2015-02-12
Facet-joint injections for people with persistent non-specific low back pain (FIS)
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2014-11-21
Multi-centre randomised control trial comparing the clinical and cost effectiveness of trans-foraminal epidural steroid injection to surgical microdiscectomy for the treatment of chronic radicular pain secondary to prolapsed intervertebral disc herniation: NErve Root Block VErsus Surgery (NERVES)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-10-08
A phase 3 multi-centre double-masked randomised controlled trial of adjunctive intraocular and periocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma; the adjunctive steroid combination in ocular trauma (ASCOT) trial
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA
Date: 2014-09-05
PREvention of Macular EDema after cataract surgery
CTID: null
Phase: Phase 3    Status: Completed
Date: 2013-03-27
Intralesional steroid injection in radiation-induced esophageal strictures
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2012-09-07
Intra-articular injection of botulinum toxin type A in hemiplegic shoulder pain: a multicentric, double blind randomised, versus steroid study.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2012-02-07
A phase II single arm, multi-centre trial of triamcinolone with a GnRH analog for castration resistant prostate cancer
CTID: null
Phase: Phase 2    Status: Completed
Date: 2011-08-15
A randomized, double-blind, double-dummy, active controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares, for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-08-08
Intramuscular corticosteroid injections in hip osteoarthritis: a double-blinded randomized controlled trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-06-27
A randomized, double-blind, active-controlled study of canakinumab (ACZ885) pre-filled syringes or reconstituted lyophilizate versus triamcinolone acetonide for treating acute gouty arthritis flares in frequently flaring patients
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-05-09
A comparative study between the Relieva Stratus MicroFlow Spacer drug eluting ethmoid sinus stent therapy and the intranasal corticoid steroid therapy in the treatment of patients with chronic rhinosinusitis
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-11-29
A controlled extension study of CACZ885H2357 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-08-09
Ensayo clínico multicéntrico aleatorizado de tres grupos paralelos para estimar la seguridad y eficacia de la Triamcinolona acetónido asociada a láser, el Bevacizumab asociado a láser frente a láser en solitario para el tratamiento del edema macular diabético difuso no traccional.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2010-07-07
Double dose treatment: Corticosteroid injection therapy in arthritis
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2010-04-21
A randomized, controlled extension study of CACZ885H2356 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-03-23
A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective
CTID: null
Phase: Phase 3    Status: Prematurely Ended, Completed
Date: 2010-03-04
Estudio aleatorizado y abierto de la eficacia, seguridad y tolerabilidad de dosis repetidas de bevacizumab intravítreo en pacientes con edema macular uveítico
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2010-02-23
Influencia del acetónido de triamcinolona y del ranibizumab en la retinopatía post irradiación en el melanoma de úvea
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2010-02-15
A multicenter double blind placebo-controlled randomised trial for benign esophageal anastomotic strictures: Savary dilation vs savary dilation with Triamcinolon
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-12-29
A single-center, randomized, controlled, observer-blind, phase IV study to develop the atopic localized eczema regression test (ALERT) using marketed topical corticosteroid formulations of different strength and the calcineurin inhibitors pimecrolimus (Elidel®) in patients with a pre-disposition for atopic dermatitis
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-12-22
A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective
CTID: null
Phase: Phase 3    Status: Prematurely Ended, Completed
Date: 2009-12-21
Intraarticular injections for hip osteoarthritis: Steroid versus Hyaluronic acid: randomised controlled trial
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2009-11-18
Valoración de la eficacia de los corticoides epidurales en el tratamiento del dolor postoperatorio y la prevención del dolor neuropático persistente en cirugía protésica de rodilla
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-07-3 e.querySelector("font strong").innerText = 'View

相关产品
联系我们